There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
-
REGULATORY New Expert Panel to Issue Proposals for 2023, 2024 Price Revisions; Official Spearheading Debate Prods Industry to Speak Up
July 29, 2022
-
BUSINESS Takeda to Lift Restricted Shipments for Leuplin in September after Over 2 Years
July 29, 2022
-
BUSINESS Mochida to Quit Filgrastim Biosimilar as Repeated Price Cuts Made It Unprofitable
July 28, 2022
-
BUSINESS GSK Japan Foresees 5% Annual Growth by 2026: President Lirette
July 28, 2022
-
BUSINESS Horizon Japan Eager for Solo Sales of Its 1st Product as Tepezza Trial Likely to Wrap Up Next Year
July 27, 2022
-
ORGANIZATION Veterans’ Group Proposes Timely Drug Re-Pricing with Online Data, Reimbursement at Actual Purchase Prices
July 27, 2022
-
ORGANIZATION JPMA Delays Announcement of Drug Pricing Proposal
July 27, 2022
-
BUSINESS BMS Has High Hopes on Eliquis Follow-Up with Less Bleeding Risks as Patent Loss Looms
July 26, 2022
-
REGULATORY Japan Confirms 1st Monkeypox Case
July 26, 2022
-
COMMENTARY Govt Should Examine Challenges with Emergency Approval Scheme Exposed by Shionogi Pill Review
July 25, 2022
-
REGULATORY KM Biologics’s Smallpox Vaccine Up for Review for Monkeypox Use
July 25, 2022
-
BUSINESS Keytruda, Opdivo, Tagrisso Breach 100 Billion Yen Sales Mark in FY2021: Tally
July 22, 2022
-
BUSINESS Shionogi to Steadily Promote PIII Trial for COVID Pill after Approval Setback
July 22, 2022
-
REGULATORY Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
July 21, 2022
-
REGULATORY MHLW Official Sees More “Specified Clinical Research” Data Used in Regulatory Submissions to Fill Industry-Academia Void
July 20, 2022
-
REGULATORY MHLW Eyes Expert Panel Launch This Summer for Drug Distribution and Pricing: Official
July 19, 2022
-
REGULATORY Japan Plans to Lower Minimum Age for Novavax Jab to 12
July 19, 2022
-
ORGANIZATION Savings from Off-Year Drug Re-Pricing Should Go Towards Medical Fees: JMA Chief
July 15, 2022
-
BUSINESS Pfizer Japan Files COVID-19 Vaccine for Ages 6 Months to 4 Years
July 15, 2022
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…